Tesamorelin Research: What the Studies Show
Tesamorelin has something almost no other research peptide has: multiple large, placebo-controlled human phase III trials and a regulatory approval behind it. Here is what each landmark trial actually measured, in plain English.
Mechanism of action
Tesamorelin is a stabilised analogue of growth hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it stimulates the pituitary to release the body's own GH in a pulsatile pattern closer to natural physiology.
The downstream effect studied most heavily is on visceral adipose tissue — the deep abdominal fat around the organs — where GH signalling drives lipolysis. The trials consistently show it targets that depot rather than subcutaneous fat.
Because it works upstream through the pituitary, the feedback loops that limit GH output stay intact, which is the mechanistic explanation offered for its comparatively clean glucose and insulin-sensitivity record across long trials.
The studies
This is one of the better-evidenced compounds in the category. Every card below is human, randomised and placebo-controlled unless stated otherwise.
Pivotal phase III efficacy
26-week phase III trial of tesamorelin for excess abdominal fat (NEJM)
Whether tesamorelin selectively reduces deep visceral fat without stripping healthy subcutaneous fat.
Double-blind, randomised, placebo-controlled · 2 mg daily · 26 weeks · CT-measured visceral adipose tissue, lipid panel and patient-reported body image endpoints
- -15.2%
- Visceral adipose tissue
- Reduced
- Triglycerides
- Visceral fat returned
- On discontinuation
- The trial that established the compound's defining property: it targets deep abdominal fat specifically, rather than causing general weight loss.
- Triglycerides fell alongside the fat reduction, and patient-reported body image improved — a rare patient-centred endpoint in this literature.
- The effect is maintenance-dependent. Visceral fat came back after the drug was stopped, which is important context for how the result should be read.
Confirmatory phase III trial and 52-week extension
Replicating the pivotal result and testing whether the effect and safety profile hold for a full year.
Large-scale randomised, placebo-controlled trial with open-label extension · 2 mg daily · 26 weeks plus extension to 52 weeks · visceral fat, waist circumference, glucose and insulin-sensitivity endpoints
- -10.9% to -15%
- Visceral fat reduction
- Decreased
- Waist circumference
- No adverse change at 52 weeks
- Glucose / insulin sensitivity
- Independently replicated the pivotal finding, which is the step most peptide research never reaches.
- The extension showed the fat reduction is sustained for as long as therapy continues — it does not plateau away or rebound while on treatment.
- Over a full year it did not worsen glucose levels or peripheral insulin sensitivity, addressing the main safety concern with GH-axis compounds.
Hepatic fat & metabolic liver disease
Tesamorelin and hepatic fat in NAFLD/MASLD (JAMA)
Whether reducing visceral fat also clears fat out of the liver.
Randomised, placebo-controlled trial · 12 months · magnetic resonance measurement of hepatic fat fraction alongside abdominal visceral fat
- -37% vs placebo
- Hepatic fat fraction
- Over one third of participants
- Reached normal liver fat (<5%)
- Liver fat drop tracked visceral fat drop
- Correlation
- Shifted the compound from a body-composition story to a metabolic-liver one — a 37% relative reduction in liver fat against placebo.
- More than a third of participants got their liver fat below the 5% normal threshold within twelve months.
- The liver improvement moved in step with the visceral fat reduction, supporting a single shared mechanism rather than two separate effects.
Modern-era confirmation
Tesamorelin efficacy alongside integrase inhibitor (INSTI) regimens
Whether the older trial results still hold now that background treatment regimens have changed.
Clinical evaluation in participants on modern integrase strand transfer inhibitor-based regimens · visceral adipose tissue and hepatic fat endpoints · metabolic safety monitoring
- -25 cm² (median)
- Visceral adipose tissue
- -4.2% absolute
- Hepatic fat
- None
- Serious metabolic events
- Confirms the effect is not an artefact of the older drug regimens used in the 2007-2014 trials.
- Both the visceral and hepatic fat effects reproduced at a similar magnitude, roughly fifteen years after the pivotal work.
- No serious metabolic perturbations were recorded, extending the safety record into current practice.
Pooled evidence
Comprehensive meta-analysis of randomised tesamorelin trials
Pooling the randomised controlled trials to establish the average effect of a standard 2 mg protocol.
Meta-analysis of randomised controlled trials of 2 mg daily tesamorelin · visceral fat, hepatic fat, lean body mass, subcutaneous fat and BMI endpoints
- -27.71 cm²
- Visceral adipose tissue
- -4.28%
- Hepatic fat
- +1.42 kg
- Lean body mass
- No significant change
- Subcutaneous fat / BMI
- The cleanest single summary of the compound: highly selective for deep abdominal fat, with a measurable reduction in liver fat.
- Lean body mass rose modestly, so the composition change is not simply tissue loss across the board.
- Subcutaneous fat and BMI did not move significantly — the scale and the skin-pinch test are the wrong instruments for measuring this effect.
Storage & handling
Tesamorelin is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.